Cargando…

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study

Continuous renal replacement therapy (CRRT) is considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care units (ICUs). However, the role of heparin anticoagulation, which is used to maintain circuit patency, is equivocal due to the r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yong Kyu, Lee, Hae Won, Choi, Kyu Hun, Kim, Beom Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193755/ https://www.ncbi.nlm.nih.gov/pubmed/25302581 http://dx.doi.org/10.1371/journal.pone.0108737

Ejemplares similares

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial
por: Choi, Ji-Young, et al.
Publicado: (2015)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
por: Sugano, Hiroshi, et al.
Publicado: (2018)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations
por: Chen, Xuanmao, et al.
Publicado: (2010)

Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production
por: Kang, Min-Woong, et al.
Publicado: (2015)

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition
por: Chen, Tao, et al.
Publicado: (2014)

Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells
por: Takada, Naoki, et al.
Publicado: (2021)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Correction: Hiroshi Sugano et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers 2018, 10, 386
por: Sugano, Hiroshi, et al.
Publicado: (2019)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
por: Lin, Yao, et al.
Publicado: (2022)

Glycogen synthase kinase‐3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells
por: Haruki, Koichiro, et al.
Publicado: (2017)

Clinical review: Patency of the circuit in continuous renal replacement therapy
por: Joannidis, Michael, et al.
Publicado: (2007)

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials
por: Xie, Yu, et al.
Publicado: (2023)

Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial
por: Hirota, Morihisa, et al.
Publicado: (2019)

Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report
por: Kawamoto, Shuji, et al.
Publicado: (2020)

Heparin/nafamostat: Bleeding and subcutaneous haematoma: case report
Publicado: (2022)

Heparin/nafamostat: Bleeding, hyperkaelemia and haemothorax: case report
Publicado: (2021)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Heparin/nafamostat: Oral cavity bleeding and alveolar hemorrhaging: case report
Publicado: (2021)

Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Crystal structure of nafamostat dimesylate
por: Fujii, Isao
Publicado: (2021)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Filter clotting with continuous renal replacement therapy in COVID-19
por: Endres, Paul, et al.
Publicado: (2020)

Filter Clotting with Continuous Renal Replacement Therapy in COVID-19
por: Rosovsky, Rachel P., et al.
Publicado: (2020)

Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis
por: Oh, Hyeon Seok, et al.
Publicado: (2022)

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
por: Park, Yeon Hee, et al.
Publicado: (2017)

Pergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease
por: Abe, Kazuo, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_lftcnmic4nhkr83bucjip86lov